201 related articles for article (PubMed ID: 21484210)
1. Control of the heparosan N-deacetylation leads to an improved bioengineered heparin.
Wang Z; Yang B; Zhang Z; Ly M; Takieddin M; Mousa S; Liu J; Dordick JS; Linhardt RJ
Appl Microbiol Biotechnol; 2011 Jul; 91(1):91-9. PubMed ID: 21484210
[TBL] [Abstract][Full Text] [Related]
2. Metabolic engineering of non-pathogenic Escherichia coli strains for the controlled production of low molecular weight heparosan and size-specific heparosan oligosaccharides.
Roy A; Miyai Y; Rossi A; Paraswar K; Desai UR; Saijoh Y; Kuberan B
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129765. PubMed ID: 33069832
[TBL] [Abstract][Full Text] [Related]
3. Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin.
Wang Z; Li J; Cheong S; Bhaskar U; Akihiro O; Zhang F; Dordick JS; Linhardt RJ
J Biotechnol; 2011 Dec; 156(3):188-96. PubMed ID: 21925548
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial one-pot chemoenzymatic synthesis of heparin.
Bhaskar U; Li G; Fu L; Onishi A; Suflita M; Dordick JS; Linhardt RJ
Carbohydr Polym; 2015 May; 122():399-407. PubMed ID: 25817684
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin.
Douaisi M; Paskaleva EE; Fu L; Grover N; McManaman CL; Varghese S; Brodfuehrer PR; Gibson JM; de Joode I; Xia K; Brier MI; Simmons TJ; Datta P; Zhang F; Onishi A; Hirakane M; Mori D; Linhardt RJ; Dordick JS
Proc Natl Acad Sci U S A; 2024 Apr; 121(14):e2315586121. PubMed ID: 38498726
[TBL] [Abstract][Full Text] [Related]
6. High cell density cultivation of recombinant Escherichia coli strains expressing 2-O-sulfotransferase and C5-epimerase for the production of bioengineered heparin.
Zhang J; Suflita M; Li G; Zhong W; Li L; Dordick JS; Linhardt RJ; Zhang F
Appl Biochem Biotechnol; 2015 Mar; 175(6):2986-95. PubMed ID: 25586487
[TBL] [Abstract][Full Text] [Related]
7. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
8. Production methods for heparosan, a precursor of heparin and heparan sulfate.
Chavaroche AA; van den Broek LA; Eggink G
Carbohydr Polym; 2013 Mar; 93(1):38-47. PubMed ID: 23465899
[TBL] [Abstract][Full Text] [Related]
9. Biosynthetic production of anticoagulant heparin polysaccharides through metabolic and sulfotransferases engineering strategies.
Deng JQ; Li Y; Wang YJ; Cao YL; Xin SY; Li XY; Xi RM; Wang FS; Sheng JZ
Nat Commun; 2024 May; 15(1):3755. PubMed ID: 38704385
[TBL] [Abstract][Full Text] [Related]
10. Immobilized enzymes to convert N-sulfo, N-acetyl heparosan to a critical intermediate in the production of bioengineered heparin.
Xiong J; Bhaskar U; Li G; Fu L; Li L; Zhang F; Dordick JS; Linhardt RJ
J Biotechnol; 2013 Sep; 167(3):241-7. PubMed ID: 23835156
[TBL] [Abstract][Full Text] [Related]
11. One-Pot Enzymatic Synthesis of Heparin from N-Sulfoheparosan.
Fu L; Linhardt RJ
Methods Mol Biol; 2022; 2303():3-11. PubMed ID: 34626365
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase.
Yu Y; Fu L; He P; Xia K; Varghese S; Dordick J; Wang H; Zhang F; Linhardt RJ
Carbohydr Polym; 2022 Nov; 295():119825. PubMed ID: 35988993
[TBL] [Abstract][Full Text] [Related]
13. Heparosan-derived heparan sulfate/heparin-like compounds: one kind of potential therapeutic agents.
Li P; Sheng J; Liu Y; Li J; Liu J; Wang F
Med Res Rev; 2013 May; 33(3):665-92. PubMed ID: 22495734
[TBL] [Abstract][Full Text] [Related]
14. Analysis of E. coli K5 capsular polysaccharide heparosan.
Ly M; Wang Z; Laremore TN; Zhang F; Zhong W; Pu D; Zagorevski DV; Dordick JS; Linhardt RJ
Anal Bioanal Chem; 2011 Jan; 399(2):737-45. PubMed ID: 20407891
[TBL] [Abstract][Full Text] [Related]
15. Escherichia coli K5 heparosan fermentation and improvement by genetic engineering.
Wang Z; Dordick JS; Linhardt RJ
Bioeng Bugs; 2011; 2(1):63-7. PubMed ID: 21636991
[TBL] [Abstract][Full Text] [Related]
16. Metabolic engineering of Escherichia coli BL21 for biosynthesis of heparosan, a bioengineered heparin precursor.
Zhang C; Liu L; Teng L; Chen J; Liu J; Li J; Du G; Chen J
Metab Eng; 2012 Sep; 14(5):521-7. PubMed ID: 22781283
[TBL] [Abstract][Full Text] [Related]
17. High density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modification.
Datta P; Fu L; Brodfuerer P; Dordick JS; Linhardt RJ
Appl Microbiol Biotechnol; 2021 Feb; 105(3):1051-1062. PubMed ID: 33481068
[TBL] [Abstract][Full Text] [Related]
18. E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor.
Wang Z; Ly M; Zhang F; Zhong W; Suen A; Hickey AM; Dordick JS; Linhardt RJ
Biotechnol Bioeng; 2010 Dec; 107(6):964-73. PubMed ID: 20717972
[TBL] [Abstract][Full Text] [Related]
19. A purification process for heparin and precursor polysaccharides using the pH responsive behavior of chitosan.
Bhaskar U; Hickey AM; Li G; Mundra RV; Zhang F; Fu L; Cai C; Ou Z; Dordick JS; Linhardt RJ
Biotechnol Prog; 2015; 31(5):1348-59. PubMed ID: 26147064
[TBL] [Abstract][Full Text] [Related]
20. High cell density cultivation of a recombinant E. coli strain expressing a key enzyme in bioengineered heparin production.
Restaino OF; Bhaskar U; Paul P; Li L; De Rosa M; Dordick JS; Linhardt RJ
Appl Microbiol Biotechnol; 2013 May; 97(9):3893-900. PubMed ID: 23318839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
